Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as as opposed with imatinib, for the initial-line treatment of CML-CP. Five hundred and nineteen patients with recently diagnosed CML-CP were being randomly assigned to acquire dasatinib in a dose of a hundred mg once each day (259 patients) https://fanz964puz7.ambien-blog.com/profile